The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Open accessAbstract
PURPOSE: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS: A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). RESULTS: Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing—initial testing of priority genes followed by expanded testing—was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. CONCLUSION: This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Self-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Self-citationCancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Self-citationCancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0996 · Cited by 934
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Study, T. P., Schumacher, F. R., (APCB), A. P. C. B., Study, T. I., Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium (BPC3), The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, (CAPS), C. O. T. P. I. S., Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), The Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0142-8 · Cited by 902
Self-citationMohler, J., Bahnson, R. R., Boston, B., Busby, J. E., D'Amico, A., Eastham, J. A., Enke, C. A., George, D., Horwitz, E. M., Huben, R. P., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0012 · Cited by 897
Self-citationCastro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., Govindasami, K., Guy, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1882 · Cited by 850
Cited by
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Self-citationNetto, G. J., Amin, M. B., Berney, D. M., Compérat, E. M., Gill, A. J., Hartmann, A., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.07.002 · Cited by 316
Epidemiology and genomics of prostate cancer in Asian men
Zhu, Y., Mo, M., Wei, Y., Wu, J., Pan, J., Freedland, S. J., Zheng, Y., & Ye, D. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00442-8 · Cited by 287
Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Bedrosian, I., Somerfield, M. R., Achatz, M. I., Boughey, J. C., Curigliano, G., Friedman, S., Kohlmann, W. K., Kurian, A. W., Laronga, C., Lynce, F., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02225 · Cited by 216
Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline
Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02608 · Cited by 64
Self-citation
Metadata
- Authors
- Giri, V. N., Knudsen, K. E., Kelly, W. K., Cheng, H. H., Cooney, K. A., Cookson, M. S., Dahut, W., Weissman, S., Soule, H. R., Petrylak, D. P., Dicker, A. P., AlDubayan, S. H., Toland, A. E., Pritchard, C. C., Pettaway, C. A., Daly, M. B., Mohler, J. L., Parsons, J. K., Carroll, P. R., Pilarski, R., Blanco, A., Woodson, A., Rahm, A., Taplin, M.-E., Polascik, T. J., Helfand, B. T., Hyatt, C., Morgans, A. K., Feng, F., Mullane, M., Powers, J., Concepcion, R., Lin, D. W., Wender, R., Mark, J. R., Costello, A., Burnett, A. L., Sartor, O., Isaacs, W. B., Xu, J., Weitzel, J., Andriole, G. L., Beltran, H., Briganti, A., Byrne, L., Calvaresi, A., Chandrasekar, T., Chen, D. Y. T., Den, R. B., Dobi, A., Crawford, E. D., Eastham, J., Eggener, S., Freedman, M. L., Garnick, M., Gomella, P. T., Handley, N., Hurwitz, M. D., Izes, J., Karnes, R. J., Lallas, C., Languino, L., Loeb, S., Lopez, A. M., Loughlin, K. R., Lu-Yao, G., Malkowicz, S. B., Mann, M., Mille, P., Miner, M. M., Morgan, T., Moreno, J., Mucci, L., Myers, R. E., Nielsen, S. M., O’Neil, B., Pinover, W., Pinto, P., Poage, W., Raj, G. V., Rebbeck, T. R., Ryan, C., Sandler, H., Schiewer, M., Scott, E. M. D., Szymaniak, B., Tester, W., Trabulsi, E. J., Vapiwala, N., Yu, E. Y., Zeigler-Johnson, C., & Gomella, L. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-08-20
- Volume
- 38
- Issue
- 24
- Pages
- 2798-2811
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3033920919
- Cited by
- 275
- References
- 76
- FWCI
- 23.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. https://app.cochat.ai/papers/10.1200/jco.20.00046
- The paper
- Giri, V. N., Knudsen, K. E., Kelly, W. K., Cheng, H. H., Cooney, K. A., Cookson, M. S., Dahut, W., Weissman, S., Soule, H. R., Petrylak, D. P., Dicker, A. P., AlDubayan, S. H., Toland, A. E., Pritchard, C. C., Pettaway, C. A., Daly, M. B., Mohler, J. L., Parsons, J. K., Carroll, P. R., . . . Gomella, L. G. (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.00046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.